scispace - formally typeset
M

Markus Ringnér

Researcher at Science for Life Laboratory

Publications -  128
Citations -  18610

Markus Ringnér is an academic researcher from Science for Life Laboratory. The author has contributed to research in topics: Gene expression profiling & Breast cancer. The author has an hindex of 49, co-authored 119 publications receiving 15744 citations. Previous affiliations of Markus Ringnér include VTT Technical Research Centre of Finland & Lund University.

Papers
More filters
Journal ArticleDOI

Normalization of Illumina Infinium whole-genome SNP data improves copy number estimates and allelic intensity ratios

TL;DR: The proposed normalization strategy represents a valuable tool that improves the quality of data obtained from Illumina Infinium arrays, in particular when used for LOH and copy number variation studies.
Journal ArticleDOI

High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer

TL;DR: A comprehensive survey of CNAs in HER2+ breast tumors is performed, pinpointing significant genomic alterations including both known and potentially novel therapeutic targets, which sheds further light on the genomically complex and heterogeneous nature of HER2- tumors in relation to other subgroups of breast cancer.
Journal ArticleDOI

Folding free energies of 5'-UTRs impact post-transcriptional regulation on a genomic scale in yeast.

TL;DR: It is concluded that there is a widespread bias for 5′-UTRs to be weakly folded, folding free energies of 5′–untranslated regions (UTRs) are correlated with mRNA translation and turnover on a genomic scale, and transcripts with strongly foldable genes are often rare and hard to find experimentally.
Journal ArticleDOI

Genomic profiling of malignant melanoma using tiling-resolution arrayCGH.

TL;DR: For the first time, alterations of the various melanoma genes were associated with distinct chromosomal imbalances suggestive of specific genomic programs in melanoma development.
Journal ArticleDOI

Gene expression profiling of primary male breast cancers reveals two unique subgroups and identifies N-acetyltransferase-1 (NAT1) as a novel prognostic biomarker

TL;DR: The aim of the present study was to characterize MBC tumors transcriptionally, to classify them into comprehensive subgroups, and to compare them with female breast cancer (FBC), and to identify NAT1 as a possible prognostic biomarker for MBC.